CBL-514 (Adipocyte Apoptosis Injection)

CBL-514 is an injectable small molecule developed by Caliway Biopharmaceuticals. The company describes it as a first-in-class drug that selectively induces adipocyte apoptosis, the programmed death of fat cells, at the site of injection. The intended result is fewer fat cells in a treated area such as the abdomen, rather than a change in total body weight.

That distinction is why it belongs in this section and why it is easy to misread. Every incretin drug on this site works systemically: it reduces appetite and therefore weight across the whole body. CBL-514 addresses a different complaint, fat that stays in one place even when weight comes down. It is a small molecule, not a peptide. We cover it because Caliway is increasingly positioning it alongside the GLP-1 drugs rather than against them.

The pivotal Phase 3 trial, SUPREME-01 (NCT07140939), began enrollment in the United States and Canada in August 2026 after an ethics board approved a protocol amendment. It is a randomised, double-blind, placebo-controlled study of about 300 people. The primary endpoint combines at least a 13% MRI-measured reduction in abdominal fat with at least a two-grade improvement on a patient-rated scale, and primary completion is estimated for May 2027. The FDA first cleared the trial in July 2025, so it started roughly a year later than planned. A second Phase 3, SUPREME-02, was cleared in May 2026.

In August 2026 the FDA also cleared a Phase 2 study, CBL-0201WR, that pairs CBL-514 with tirzepatide in about 120 adults with overweight or obesity. Its primary measure is abdominal subcutaneous fat on MRI, with body weight, visceral fat, and lean mass as exploratory measures. CBL-514 is investigational, not approved anywhere, and not commercially available. With Phase 3 primary completion not expected until 2027, any approval is several years away.

According to Caliway, CBL-514 inhibits DYRK1B, a kinase involved in cell survival, and pushes fat cells toward apoptosis by raising caspase-3 activity and the ratio of the pro-death protein Bax to the protective protein Bcl-2. The company describes a dose-dependent effect on fat cells alongside increased breakdown of stored fat. The chemical structure has not been disclosed, and the mechanistic detail comes from the company rather than from independent replication.

The better comparison is with existing fat-reduction procedures, not with semaglutide. The one approved injectable for localised fat, deoxycholic acid for fat under the chin, destroys fat cells by disrupting their membranes. Apoptosis is a more orderly form of cell death, and Caliway argues this explains why the side effects reported so far are mostly mild injection-site reactions. That argument is plausible, but the two approaches have not been compared directly.

CBL-514 is a credible attempt at a real problem: a drug for localised fat that would sit beside surgery and devices rather than beside appetite suppressants. The Phase 2b result is large and placebo-controlled, which is more than most aesthetic-medicine candidates offer at this stage. What it lacks is independent data, long-term durability, and a published Phase 3. The visceral-fat and tirzepatide-combination stories are interesting hypotheses, and both currently rest on small or animal datasets.